## **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application:

## **LISTING OF CLAIMS:**

Claims 1-2. canceled.

Claim 3. (previously presented): A 1,25-dihydroxy-2-methylvitamin  $D_3$  compound, wherein the compound is

- (i) (20S)- $1\alpha$ , 25-dihydroxy- $2\beta$ -methyl- $3\beta$ -vitamin  $D_3$ ;
- (ii) (20S)-1  $\beta$ , 25-dihydroxy-2 $\beta$ -methyl-3 $\alpha$  -vitamin D<sub>3</sub>;
- (iii) (20S)- $1\alpha$ , 25-dihydroxy- $2\alpha$  -methyl- $3\beta$ -vitamin D<sub>3</sub>; or
- (iv) (20S)- $1\alpha$ , 25-dihydroxy- $2\alpha$ -methyl- $3\alpha$ -vitamin D<sub>3</sub>.

Claim 4. (currently amended): A method for producing a vitamin D<sub>3</sub> compound described in claim 3, comprising reacting an exo-methylene compound of formula (II):

wherein X is a bromine atom or an iodine atom, with an eneyne compound of formula (III):

Amendment Under 37 C.F.R. § 1.312 U.S. Application No. 10/214,155

Q52816

wherein R3-R3 and R4-R4 are each independently a hydrogen atom or a tri ( $C_1$  to  $C_7$  hydrocarbon) silyl) silyl group in the presence of a palladium catalyst, and optionally removing the protecting group of the tri ( $C_1$  to  $C_7$  hydrocarbon) silyl) silyl group, and further wherein the vitamin  $D_3$  compound is

- (i)  $(20S)-1\alpha$ , 25-dihydroxy-2 $\beta$ -methyl-3 $\beta$ -vitamin D<sub>3</sub>;
- (ii) (20S)-1 $\beta$ , 25-dihydroxy-2 $\beta$ -methyl-3 $\alpha$ -vitamin D<sub>3</sub>;
- (iii) (20S)- $1\alpha$ , 25-dihydroxy- $2\alpha$ -methyl- $3\beta$ -vitamin D<sub>3</sub>; or
- (iv) (20S)- $1\alpha$ , 25-dihydroxy- $2\alpha$ -methyl- $3\alpha$ -vitamin D<sub>3</sub>.